Abstract

In cardiovascular disease, the protective NO/sGC/cGMP signalling-pathway is impaired due to a decreased pool of NO-sensitive haem-containing sGC accompanied by a reciprocal increase in NO-insensitive haem-free sGC. However, no direct method to detect cellular haem-free sGC other than its activation by the new therapeutic class of haem mimetics, such as BAY 58-2667, is available. Here we show that fluorescence dequenching, based on the interaction of the optical active prosthetic haem group and the attached biarsenical fluorophor FlAsH can be used to detect changes in cellular sGC haem status. The partly overlap of the emission spectrum of haem and FlAsH allows energy transfer from the fluorophore to the haem which reduces the intensity of FlAsH fluorescence. Loss of the prosthetic group, e.g. by oxidative stress or by replacement with the haem mimetic BAY 58-2667, prevented the energy transfer resulting in increased fluorescence. Haem loss was corroborated by an observed decrease in NO-induced sGC activity, reduced sGC protein levels, and an increased effect of BAY 58-2667. The use of a haem-free sGC mutant and a biarsenical dye that was not quenched by haem as controls further validated that the increase in fluorescence was due to the loss of the prosthetic haem group. The present approach is based on the cellular expression of an engineered sGC variant limiting is applicability to recombinant expression systems. Nevertheless, it allows to monitor sGC's redox regulation in living cells and future enhancements might be able to extend this approach to in vivo conditions.

Highlights

  • The heterodimeric a/b haemprotein soluble guanylate cyclase is the physiological receptor for the endogenous gaseous messenger nitric oxide (NO)

  • We assumed that the N-terminus would be in proximity of the haem as observed in the crystal structure of the haem nitric oxide oxygen (H-NOX) domain of Nostoc sp. [2]

  • The NO/soluble guanylate cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway has been shown to be impaired in various cardiovascular diseases mainly by a reduced bioavailability of NO and, in parallel, by reducing the sensitivity of sGC towards its agonist NO [5,7,25,26,27]

Read more

Summary

Introduction

The heterodimeric a/b haemprotein soluble guanylate cyclase (sGC) is the physiological receptor for the endogenous gaseous messenger nitric oxide (NO). Impairment of the NO/ sGC/cGMP pathway has been linked to the development of various cardiovascular diseases such as heart failure or arterial hypertension [5]. The prosthetic haem group of sGC has a pivotal role in the activation and stabilisation of the enzyme and its oxidation or removal renders sGC insensitive to NO. I.e. the formation of reactive oxygen species (ROS) such as O22, has been associated with various cardiovascular diseases [5]. ROS are known to interfere with the NO/sGC/cGMP signalling-pathway via O22-mediated scavenging of NO and intermediate peroxynitrite formation, which in turn oxidizes the sGC haem to the NOinsensitive Fe3+ state [6,7,8]. It was shown that haemfree sGC is prone to ubiquitin-mediated degradation [13,16]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call